Amytrx has commenced the Phase II clinical trial of its lead drug candidate, AMTX-100 CF3, to treat atopic dermatitis (AD).

A peptide, AMTX-100 CF3 is in a topical ointment formulation that penetrates the skin easily. 

Made of 87% water, it leaves no odour or residue. 

AMTX-100 CF3 is claimed to have the potential to transport across membranes, addressing inflammation and modulating immune-mediated ailments than just hindering inflammation.

Amytrx is launching the trial in adult participants with mild to moderate atopic dermatitis utilising transcriptomic mapping. 

Amarex Clinical Research designed the trial, which will assess the safety and efficacy of AMTX-100 CF3 over 28 days. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also filed an investigational new drug (IND) application with the Food and Drug Administration (FDA), guided Amytrx through the Phase I trial and is set to lead the product through FDA trials until it receives approval for marketing.

Amytrx intends to expand to adolescent and juvenile participants during its Phase II trial depending on the safety profile of AMTX-100 CF3 in Phase I/II. 

The companies concluded the Phase I human safety and exploratory efficacy trial of the drug last year. 

According to the trial data, 50% of the patients in a seven-day treatment protocol attained total or almost total clearance of treated AD lesions following one week of AMTX-100 CF3 administration.

In addition, the improvement trend continued even after concluding the treatment as well as through the two-week follow-up period.

Amytrx chief business officer Randy Riggs said: “We are encouraged by the biological impact on patients in this study for their treatment with a therapeutic we believe is not only effective but is supportive of compliance.” 

“We’re excited by the potential of our peptide therapeutic that doesn’t inhibit, but safely modulates inflammation to bring about the resolution of immune-mediated diseases.”